

Current level of influenza activity: Medium

Influenza activity trend: Increasing

Confirmed influenza cases since 2022 week 40: **5427** (2205 influenza A(H3N2), 1204 influenza A(H1N1)pdm09, 1931 influenza A(not subtyped) and 87 influenza B)

Key points – Wales


Influenza circulates in Wales and confirmed cases of RSV remain at very high intensity levels.

During Week 51 (ending 25/12/2022) there were 1877 cases of influenza (a large increase from the previous week), with a further seven cases from previous weeks. Influenza is currently circulating in Wales. COVID-19 cases also continue to be detected in symptomatic patients in hospitals and in the community. RSV incidence in children under five years of age has decreased, but remains at <u>very high levels</u> of activity (compared to the 10 seasons leading up to 2020). Rhinovirus, RSV and Infuenza A are the most commonly detected causes of non-COVID-19 Acute Respiratory Infection (ARI), but other causes have increased in recent weeks, including: human metapneumovirus, adenovirus and seasonal coronaviruses.

- The Sentinel GP consultation rate for influenza-like illness (ILI) in Wales during week 51, was 34.4 consultations per 100,000 practice population (Table 1). This is an increase compared to the previous week (24.2 consultations per 100,000) and has exceeded the threshold for medium intensity levels (Figure 1). Consultation rates were highest in those aged 25 to 44 years.
- The Sentinel GP consultation rate for Acute Respiratory Infections (ARI) was 603.9 per 100,000 practice population during Week 51, an increase compared to the previous week (514.8 per 100,000) (Table 2 and Figure 3). Weekly consultations for both Lower Respiratory Tract Infections and Upper Respiratory Tract Infections increased compared to the previous week.
- The percentage of calls to **NHS Direct Wales** which were 'influenza-related' (cold/flu, cough, fever, headache and sore throat) during Week 51 decreased to 35.9% (Figure 9).
- During Week 51, 2,853 specimens received multiplex respiratory panel testing mainly from patients attending hospitals. These results do not include samples tested solely for SARS-CoV-2. There were **1030** samples positive for influenza of which 352 were A(H1N1), 598 were A(H3N2), 67 were A(not typed), and 13 were influenza B. Overall influenza positivity was 36.1% across all age groups; 35.4% in those aged 18 years and over; and 37.9% in those aged under 18 years. In addition, there were 435 SARS-CoV-2, 305 rhinovirus, 292 RSV, 189 human metapneumonovirus, 185 adenovirus, 145 seasonal coronavirus, 55 parainfluenza, and 35 enterovirus positive samples (Figure 5). Additionally, 2,748 samples from patients were tested for influenza, RSV and SARS-CoV-2 only, many of these tests may be associated with screening activities rather than diagnostic testing for patients presenting with ARI symptoms. Of these, 825 were positive for influenza A, eight for influenza B, 597 were positive for SARS-CoV-2 and 174 were positive for RSV (Figure 6). Furthermore, 117 respiratory specimens were tested from patients in intensive care units (ICU) of which 24 were positive for influenza (eight A(H3N2), four A(H1N1) and 12 A(not subtyped) (Figure 7).
- There were 34 surveillance samples from patients with ILI symptoms collected by sentinel GPs and community pharmacies during Week 51. Of the 34 samples, 14 samples tested positive for influenza (ten A(H3N2), and three A(H1N1)), one for RSV, one for rhinovirus, two for human metapneumovirus, three for SARS-CoV2, two for enterovirus, one for a seasonal coronavirus, and one for adenovirus (as at 29/12/2022) (Figure 4).
- Confirmed RSV case incidence in children aged under five has substantially decreased compared to previous weeks but remains at <u>very high</u> intensity levels. In week 51 there were 80.6 confirmed cases per 100,000 in this age group (Figure 7).
- The 7-day rolling sum of cases hospitalised within 28 days of an influenza positive test result in the community (or up to two days post-admission) increased to 369 during week 51, from 236 cases in week 50 (figure 10).
- During Week 51, 86 **ARI outbreaks** were reported to the Public Health Wales Health Protection team. Of the 86 outbreaks, 84 were reported as COVID-19 and two as influenza A. Of these 86 **ARI outbreaks**, 80 were reported in residential care homes, two in schools, one in hospital setting and three in community/mixed or other setting.
- According to **<u>EuroMoMo</u>** analysis, all-cause deaths in Wales were not significantly in excess during week 49.


Respiratory infection activity in Wales

Figure 1. Clinical consultation rate for ILI per 100,000 practice population in Welsh sentinel practices (as of 25/12/2022).



* The Moving Epidemic Method (MEM) threshold calculated for Wales ILI consultation rates is 11.1 per 100,000. MEM thresholds used in this chart are based on influenza from 2010-11 to 2018-19 seasons. Caution should be used when comparing consultation rates from March 2020 onwards to previous periods due to the changes in health-seeking behaviours brought about by the COVID-19 pandemic. **Clinical consultations for ILI seasons are monitored from W40 to W40, the most recent data is presented in red.





* Reporting changed to Audit+ surveillance system

Table 1. Age-specific consultations (per 100,000) for ILI in Welsh sentinel practices, week 46 – week 51 2022 (as of 25/12/2022).

Age						
group	46	47	48	49	50	51
< 1	0.0	0.0	0.0	0.0	0.0	0.0
1 - 4	6.8	6.8	7.4	13.5	13.5	9.9
5 - 14	0.0	0.0	7.3	6.7	40.3	23.1
15 - 24	0.0	6.6	21.1	17.4	47.8	24.1
25 - 34	5.8	7.8	6.3	19.3	38.7	68.3
35 - 44	3.8	9.7	8.4	19.1	38.2	63.5
45 - 64	3.7	1.9	6.0	18.3	11.9	23.9
65 - 74	4.3	4.4	7.0	8.7	8.7	28.0
75+	2.2	0.0	2.4	2.2	2.2	25.1
Total	3.2	4.2	7.9	14.1	24.2	34.4

Table 2. Age-specific consultations (per 100,000) for ARI in Welsh sentinel practices, week 46 – week 51 2022 (as of 25/12/2022).

Age	46	47	48	49	50	E4
group	40	4/	40	49	50	51
< 1	1779.0	1992.4	2144.3	2704.4	2823.1	3266.8
1 - 4	1052.4	1365.4	1375.2	2742.4	2292.3	2332.9
5 - 14	304.5	436.6	539.0	1035.9	1009.0	1088.0
15 - 24	175.8	213.5	243.7	308.6	406.4	327.7
25 - 34	208.7	209.5	206.3	301.5	371.1	492.1
35 - 44	157.2	169.1	233.8	317.7	382.4	563.1
45 - 64	140.1	150.8	186.0	239.2	306.1	425.7
65 - 74	149.4	168.9	174.5	212.4	372.9	434.8
75+	159.1	151.7	245.3	266.1	355.2	464.8
Total	221.2	258.5	301.8	459.9	514.8	603.9

Figure 3. Age-specific consultations (per 100,000) for ARI in Welsh sentinel practices, week 1 – week 51 2022 (as of 25/12/2022).






Figure 4. Specimens submitted for virological testing by sentinel GPs as of 25/12/2022, by week of sample collection, week 51 2021 to week 51 2022.



* Tested negative for influenza, adenovirus, rhinovirus, RSV, parainfluenza, mycoplasma, human metapneumovirus, enterovirus, bocavirus and coronaviruses. Samples which test positive for more than on pathogen will appear more than once in the chart.



This chart summarises respiratory panel test data and does not include data for patients tested SOLEY for SARS-CoV2. Combined data for tests carried out in Public Health Wales Microbiology: Cardiff laboratory, provided by Public Health Wales Microbiology Cardiff Specialist Virology Centre. This chart summarises individual test results, patients who are positive for multiple infections within a given week will appear multiple times. Samples which test positive for more than on pathogen will appear more than once in the chart.

Figure 6. Specimens from hospital patients submitted for RSV, Influenza and SARS-CoV2 testing only, as of 25/12/2022 by week of sample collection, week 51 2021 to week 51 2022.






Figure 7. Specimens submitted for virological testing for ICU patients, by week of sample collection, week 51 2021 to Week 51 2022.




This chart summarises respiratory panel test data and does not include data for patients tested SOLELY for SARS-CoV2. Samples which test positive for more than on pathogen will appear more than once in the chart.

Figure 8. RSV incidence rate per 100,000 population aged under five years, week 30 2018 to Week 51 2022.



*RSV seasons are monitored from W30 to W29, the most recent data is presented in red

Calls to NHS Direct Wales



¹ Data supplied by Health Statistics and Analysis Unit, Welsh Government.

Flu related calls are the sum of calls recorded as 'cold/flu', 'cough', 'headache', 'fever' and 'sore throat'. Following changes to the NHS Direct calls system, including the start of the 111 pilot, there has been a change in the way in which denominator data are calculated for this chart, NHS Direct Wales now count the total number of nurse triaged calls (i.e. calls which could have symptom data recorded against them), note that 111 includes out-of-hours calls.

Table 3. Uptake of influenza immunisations in GP Practice patients in Wales 2022/23 (as of 27/12/2022).


Influenza immunisation uptake in the 2022/23 season				
People aged 65y and older	74.5%			
People younger than 65y in a clinical risk group	41.0%			
Children aged two & three years	39.9%			
Children aged between four & ten years	59.4%			
Children aged between 11 & 15 years	50.1%			
Total NHS staff	41.6%			
NHS staff with direct patient contact	41.3%			

Uptake in other eligible groups will be available in the coming weeks.

The end of season report Influenza in Wales 2019/20 is available to download and contains a full breakdown of vaccination uptake amongst eligible groups.

Link to report: https://phw.nhs.wales/topics/immunisation-and-vaccines/fluvaccine/annual-influenza-surveillance-and-influenza-vaccination-uptakereports/

Figure 10. Seven day rolling sum of cases hospitalised in Wales within 28 days of an influenza or RSV positive test result in the community (or up to 2 days post-admission), as of 25/12/2022).



Influenza activity – UK and international summary

- As of week 50, GP ILI consultations increased in Northern Ireland to 9.4 per 100,000, and in Scotland to 11.3 per 100,000. The weekly ILI GP consultation rate in England reported through the RCGP system increased to 23.9 per 100,000.
- During week 50, 1,739 samples tested positive for influenza were reported in England (including 47 A(H1N1)pdm09, 372 A(H3N2), 1,274 A(not subtyped) and 46 influenza B). Overall influenza positivity increased to 20.2%. UK summary data are available from the <u>UKHSA Influenza and COVID-19 Surveillance Report</u>.
- The WHO and the European Centre for Disease Prevention and Control (ECDC) reported in its weekly influenza update, that during week 50, nine countries reported baseline-intensity, seven reported low-intensity, 15 reported medium-intensity, six reported high-intensity, and six reported very-high intensity. From the 43 countries reporting, four reported no activity, six reported sporadic spread, four reported local spread, six reported regional spread, and 23 reported widespread activity (across the Region). During week 50, 1,376 of (31%) samples from patients presenting to all sentinel primary care centres with ILI or ARI symptoms were tested positive for influenza. This is an increase from the previous week and remains above the threshold for epidemic activity (10%). Of sentinel specimens that tested positive for influenza for the season to date, 96% were influenza A (78%% H3, and 22% A(H1N1)pdm09) and 4% were influenza B. Source: Flu News Europe: http://www.flunewseurope.org/
- The WHO reported on 23/12/2022, based on data up to 11/12/2022, that globally, influenza activity has increased, with influenza A(H3N3) predominating.
- In the temperate zones of the southern hemisphere, overall influenza was low, except for Chile, and Argentina, where influenza A(H3N2) and influenza B predominated respectively. RSV activity increased in South Africa.
- In tropical South America, influenza detections of predominantly A(H3N2) virus decreased but remained elevated in Mexico.
- In Western Africa, influenza activity remained low, although influenza B/Victoria and A(H3N2) detections were sporadically reported by Burkina Faso, Ghana, and Niger. In Middle Africa, Cameroon reported influenza B detections. In Eastern Africa, cases of influenza A and B increased.
- In Southern Asia, influenza detections of predominately A(H3N2) viruses decreased mainly due to a decrease in activity reported in Iran. Influenza A(H3N2) predominated, though detections of A(H1N1)pdm09 and influenza B viruses were also reported. In South-East Asia, influenza activity decreased apart from Malaysia. In Western Asia, influenza detections decreased, though increased activity in Qatar was reported.
- In Central Asia, specifically in Kazakhstan, influenza activity of predominantly influenza B viruses, continued to be reported. Influenza like illnesses and severe acute respiratory infections activity have also increased.
 Source: WHO influenza update:<u>https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/influenza-updates/current-influenza-update</u>
- Based on FluNet reporting (as of 22/12/2022), during the time period from 28/11/2022 11/12/2022, National Influenza Centres and other national influenza laboratories from 130 countries, areas or territories reported influenza surveillance data. The WHO Global Influenza Surveillance and Response System laboratories tested more than 447,351 specimens during that time period, of which 81,619 were positive for influenza viruses. 70,209 (97%) of those positive for influenza were typed as influenza A (of the subtyped influenza A viruses, 4,722(28.6%) were influenza A(H1N1)pdm09 and 11,791 (71.4%) were influenza A(H3N2)) and 2,410 (3%) influenza B (of the 370 characterised influenza B viruses, all belonged to the B-Victoria lineage). Source: FluNet: https://www.who.int/tools/flunet

Update on influenza activity in North America

The USA Centers for Disease Control and Prevention (CDC) report that seasonal influenza activity is at high levels, although it appeared to decline in some areas across the country during week 50 (ending 17/12/2022). Nationally, 33,202 (24.4%) out of 135,848 specimens tested positive for influenza in week 50 in clinical laboratories nationwide, of these positives, 33,041 (99.5%) were influenza A and 161 (0.5%) were influenza B. Further characterisation has been carried out on 9,081 specimens by public health laboratories, and 1,588 samples tested positive for influenza; 182 influenza A(H1N1)pdm09 (22.2%), 637 influenza A(H3N2) (77.8%), 764 influenza A(not subtyped) and three influenza B.

Source: CDC Weekly US Influenza Surveillance Report: <u>http://www.cdc.gov/flu/weekly/</u>

• The Public Health Agency of Canada reported that during week 49, influenza activity along with most surveillance indicators remained above expected levels, with some reporting small decreases. During week 49, 9,393 influenza detections were reported: 9,365 influenza A (predominantly A(H3N2) at 95%), and 28 influenza B. The percentage of ILI visits rose to 4.0% in week 48.

Source: Public Health Agency of Canada: <u>https://www.canada.ca/en/public-health/services/diseases/flu-influenza/influenza-surveillance/weekly-influenza-reports.html</u>

Respiratory syncytial virus (RSV) in North America

The USA CDC reported RSV positivity rate and detections both decreased in the week beginning 10/12/2022.
<u>Source: CDC RSV national trends: https://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html</u>

COVID-19 – UK and international summary

- As of 21/12/2022, there were 32 new positive PCR episodes, for the most recent 7-day reporting period, per 100,000 population in Wales. There were 15 suspected COVID-19 deaths with a date of death in the most recent 7-day reporting period, reported to Public Health Wales. There were 31 COVID-19 death registrations in the last reporting period reported by ONS. Latest COVID-19 data from Public Health Wales is available from: https://phw.nhs.wales/topics/latest-information-on-novel-coronavirus-covid-19/
- The latest UKHSA COVID-19 data summary is available from: https://coronavirus.data.gov.uk/
- WHO situation updates on COVID-19 are available from: https://covid19.who.int/

Middle East respiratory syndrome coronavirus (MERS-CoV) – latest update from WHO and ECDC

 On 16/11/22 WHO reported four laboratory-confirmed cases of locally acquired Middle East Respiratory Syndrome coronavirus (MERS-CoV) in the Kingdom of Saudi Arabia from 29/12/2021 to 31/10/2022. This follows on from one laboratory-confirmed case in Oman reported on 28/04/2022, and two (including 1 death) reported from Qatar between 22/03/2022 to 03/04/2022. Since the beginning of 2022 and as of 22/11/2022 there have been six reported cases of MERS-CoV, with an additional case reported from 29/12/2022. As of 16/11/2022, 2,600 laboratory confirmed cases of human infection with MERS-CoV, including 935 associated deaths, from across the globe have officially been reported to WHO since 2012.

Source: WHO Global Alert and Response website: <u>https://www.who.int/emergencies/disease-outbreak-news</u>

- The majority of the MERS cases continue to be reported from Middle Eastern countries within the Arabian Peninsula, and specifically from Saudi Arabia. Rapid risk assessments of the situation from ECDC, which contain epidemiological updates and advice for travellers and healthcare workers, are available from: <u>https://ecdc.europa.eu/en/middle-east-respiratory-syndrome-coronavirus</u>
- Further updates and advice for healthcare workers and travellers are available from WHO: <u>http://www.who.int/emergencies/mers-cov/en/</u> and from NaTHNaC: <u>https://travelhealthpro.org.uk/news/237/mers-cov-update-travelhealthpro-country-pages</u>

Human infection with avian influenza A(H7N9), China

The latest WHO Influenza at Human-Animal Interface summary (31/08/2022 – 05/10/2022) reports that there have been no publicly available reports from China or other countries on influenza A(H7N9) in recent months. Since February 2013, a total of 1,568 laboratory-confirmed cases of human infection with avian influenza A(H7N9), including at least 616 deaths, have been reported to the global influenza programme: https://www.who.int/teams/global-influenza-programme/avian-influenza/monthly-risk-assessment-summary The risk of international spread of avian influenza A(H7N9) is considered to be low at present. However, it is important that clinicians are aware of the possibility of human infection with animal influenza, in persons presenting with severe acute respiratory disease, while travelling or soon after returning from an area where avian influenza is a concern. WHO Global Alert & Response updates: https://www.who.int/emergencies/disease-outbreak-news

Links: Public Health Wales influenza surveillance webpage: http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=25480

Public Health Wales COVID-19 data dashboard: https://phw.nhs.wales/topics/latest-information-on-novel-coronavirus-covid-19/

Public Health Wales interactive report on hospitalisations in influenza and RSV cases: <u>https://public.tableau.com/app/profile/public.health.wales.health.protection/viz/ARI-Hospitaladmissionsdashboard/ARIhospitaladmissionsdashboard?publish=yes</u>

GP Sentinel Surveillance of Infections Scheme: http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=27918

NICE influenza antiviral usage guidance: http://www.nice.org.uk/Guidance/TA158

England influenza and COVID-19 surveillance: https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2022-to-2023-season

Scotland seasonal respiratory surveillance:

https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/weekly-national-seasonalrespiratory-report/

Northern Ireland influenza surveillance: https://www.publichealth.hscni.net/directorate-public-health/health-protection/seasonal-influenza

European Centre for Communicable Disease: <u>http://ecdc.europa.eu/</u>

European influenza information: <u>http://flunewseurope.org/</u>

Advice on influenza immunisation https://phw.nhs.wales/topics/immunisation-and-vaccines/fluvaccine/

Advice on influenza immunisation (for intranet users) Influenza (sharepoint.com)

For further information on this report, please email Public Health Wales using: <u>surveillance.requests@wales.nhs.uk</u>